-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Valproic-acid-d14-sodium
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/valproic-acid-d14-sodium.gif)
| Category | Human immunodeficiency Virus (HIV) |
| Description | Valproic acid-d14-sodium is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 M), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid is used in the treatment of epilepsy, bipolar disorder, Metabolic disease, HIV infection and prevention of migraine headaches. |
Product Information
| Molecular Weight | 180.28 |
| Molecular Formula | C8H16NaO2 |
| Purity | ≥98% (HPLC) |
| Solubility | DMSO: 78 mg/mL (199.58 mM) Water: 78 mg/mL (199.58 mM) Ethanol: Insoluble |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| In Vitro | Valproic acid (VPA) (0-15 mM; 24 and 72 h) inhibits Hela cell growth in a dose- and time- dependent manner. Valproic acid (10 mM; 24 h) significantly attenuates the activities of total, cytosol and nuclear HDACs. Valproic acid (0-15 mM; 24 h) induces a G1 phase arrest at 1-3 mM and a G2/M phase arrest at 10 mM, and increases the percentage of sub-G1 cells in HeLa cells. Valproic acid also induces necrosis, Apoptosis and Lactate dehydrogenase (LDH) release. Valproic acid (0-20 mM; 24 h) activates Tcf/Lef-dependent transcription and synergizes with lithium. Valproic acid (0-5 mM; 0-18 h) increases β-catenin levels in Neuro2A cells. Valproic acid (0-2 mM; 0-24 h) stimulates phosphorylation of AMPK and ACC in hepatocytes. Valproic acid (0-10 mM; 2 days) induces Notch1 signaling and morphologic differentiation, suppresses production of NE tumor markers in SCLC cells. |
| In Vivo | Valproic acid (VPA) (500 mg/kg; i.p.; daily for 12 days) inhibits tumor angiogenesis in mice transplanted with Kasumi-1 cells. Valproic acid (350 mg/kg; i.p.; once) enhances social behavior in rats. Valproic acid (0.26% (w/v); p.o. via drinking water; 14 days) decreases liver mass, hepatic fat accumulation, and serum glucose in obese mice without hepatotoxicity. |
| PSA | 60.36000 |
| Target | HDAC; Autophagy; Mitophagy; HIV; Notch; Endogenous Metabolite |
